[1]

San Juan Galán J, Poliquin V, Gerstein AC. 2023. Insights and advances in recurrent vulvovaginal candidiasis. PLoS Pathogens 19(11):e1011684

doi: 10.1371/journal.ppat.1011684
[2]

Willems HME, Ahmed SS, Liu J, Xu Z, Peters BM. 2020. Vulvovaginal candidiasis: a current understanding and burning questions. Journal of Fungi 6(1):27

doi: 10.3390/jof6010027
[3]

Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, et al. 2021. Sexually transmitted infections treatment guidelines, 2021. MMWR Recommendations and Reports 70(4):1−187

doi: 10.15585/mmwr.rr7004a1
[4]

Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, et al. 2016. Executive summary: clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clinical Infectious Diseases 62(4):409−417

doi: 10.1093/cid/civ1194
[5]

Intra J, Sala MR, Brambilla P, Carcione D, Leoni V. 2022. Prevalence and species distribution of microorganisms isolated among non-pregnant women affected by vulvovaginal candidiasis: a retrospective study over a 20 year-period. Journal of Medical Mycology 32(3):101278

doi: 10.1016/j.mycmed.2022.101278
[6]

Donders G, Sziller IO, Paavonen J, Hay P, de Seta F, et al. 2022. Management of recurrent vulvovaginal candidosis: narrative review of the literature and European expert panel opinion. Frontiers in Cellular and Infection Microbiology 12:934353

doi: 10.3389/fcimb.2022.934353
[7]

Pan Y, Sun Y, Chen L, Cheng Y, Jin P, et al. 2023. Candida causes recurrent vulvovaginal candidiasis by forming morphologically disparate biofilms on the human vaginal epithelium. Biofilm 6:100162

doi: 10.1016/j.bioflm.2023.100162
[8]

Fleiss JL, Levin B, Paik MC. 2003. Statistical Methods for Rates and Proportions. Hoboken, N.J.: John Wiley & Sons Inc. pp. 760 doi: 10.1002/0471445428

[9]

Okungbowa FI, Isikhuemhen OS, Dede AP. 2003. The distribution frequency of Candida species in the genitourinary tract among symptomatic individuals in Nigerian cities. Revista Iberoamericana de Micologia 20(2):60−63

[10]

Enweani IB, Gugnani HC, Okobia R, Ojo SB. 2001. Effect of contraceptives on the prevalence of vaginal colonization with Candida species in Edo State, Nigeria. Revista Iberoamericana de Micologia 18(4):171−173

[11]

de Souza CM, Dos Santos MM, Furlaneto-Maia L, Furlaneto MC. 2023. Adhesion and biofilm formation by the opportunistic pathogen Candida tropicalis: what do we know? Canadian Journal of Microbiology 69(6):207−218

doi: 10.1139/cjm-2022-0195
[12]

Ogba OM, Chidinma BD, Inah IO, Ogba RO, Akpan NG, et al. 2024. Catheter associated Candiduria among in-patients accessing care in a Tertiary Health Institution in Calabar, Nigeria. Sokoto Journal of Medical Laboratory Science 9(3):227−236

doi: 10.4314/sokjmls.v9i3.24
[13]

Coignard C, Hurst SF, Benjamin LE, Brandt ME, Warnock DW, et al. 2004. Resolution of discrepant results for Candida species identification by using DNA probes. Journal of Clinical Microbiology 42:858−861

doi: 10.1128/jcm.42.2.858-861.2004
[14]

Harriott MM, Lilly EA, Rodriguez TE, Fidel PL, Noverr MC. 2010. Candida albicans forms biofilms on the vaginal mucosa. Microbiology 156:3635−3644

doi: 10.1099/mic.0.039354-0
[15]

Espinel-Ingroff A. 2022. Commercial methods for antifungal susceptibility testing of yeasts: strengths and limitations as predictors of resistance. Journal of Fungi 8(3):309

doi: 10.3390/jof8030309
[16]

Clinical and Laboratory Standards Institute (CLSI). 2022. Performance standards for antifungal susceptibility testing of yeasts (3rd ed., CLSI supplement M27M44S)

[17]

Farr A, Effendy I, Frey Tirri B, Hof H, Mayser P, et al. 2021. Guideline: vulvovaginal candidosis (AWMF 015/072, level S2k). Mycoses 64(6):583−602

doi: 10.1111/myc.13248
[18]

Sherrard J, Donders G, White D, Jensen JS. 2011. European (IUSTI/WHO) guideline on the management of vaginal discharge. International Journal of STD & AIDS 22(8):421−429

doi: 10.1258/ijsa.2011.011012
[19]

Gaziano R, Sabbatini S, Monari C. 2023. The interplay between Candida albicans, vaginal mucosa, host immunity and resident microbiota in health and disease: an overview and future perspectives. Microorganisms 11(5):1211

doi: 10.3390/microorganisms11051211
[20]

Cavalheiro M, Teixeira MC. 2018. Candida biofilms: threats, challenges, and promising strategies. Frontiers in Medicine 5:28

doi: 10.3389/fmed.2018.00028
[21]

Bitew A, Abebaw Y. 2018. Vulvovaginal candidiasis: species distribution of Candida and their antifungal susceptibility pattern. BMC Women’s Health 18:94

doi: 10.1186/s12905-018-0607-z
[22]

Bhattacharya S, Sae-Tia S, Fries BC. 2020. Candidiasis and mechanisms of antifungal resistance. Antibiotics 9(6):312

doi: 10.3390/antibiotics9060312
[23]

Cornely OA, Sprute R, Bassetti M, Chen SCA, Groll AH, et al. 2025. Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASM. The Lancet Infectious Diseases 25(5):e280−e293

doi: 10.1016/S1473-3099(24)00749-7
[24]

Donders GGG, Bellen G, Ruban K, Van Bulck B. 2018. Short- and long-term influence of the levonorgestrel-releasing intrauterine system (Mirena®) on vaginal microbiota and Candida. Journal of Medical Microbiology 67(3):308−313

doi: 10.1099/jmm.0.000657
[25]

Pfaller MA, Diekema DJ, Turnidge JD, Castanheira M, Jones RN. 2019. Twenty years of the SENTRY antifungal surveillance program: results for Candida species from 1997−2016. Open Forum Infectious Diseases 6(1):S79−S94

doi: 10.1093/ofid/ofy358